Abstract:Jianlan Peng, 1 Shiying Li, 2 Huihui Ti 1, 3 1 School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China; 2 Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China; 3 Guangdong Province Precise Medicine and Big Data Engineering Technology Research Center for Traditional Chinese Medicine, Guangzhou, People's Republic of China Correspondence: Huihui Ti; Shiying Li, Email ; Low immunogenicity of tumors poses a challenge in the development of effective tumor immunotherapy. However, emerging evidence suggests that certain therapeutic approaches, such as chemotherapy, radiotherapy, and phototherapy, can induce varying degrees of immunogenic cell death (ICD). This ICD phenomenon leads to the release of tumor antigens and the maturation of dendritic cells (DCs), thereby enhancing tumor immunogenicity and promoting immune responses. However, the use of a single conventional ICD inducer often fails to achieve in situ tumor ablation and establish long-term anti-tumor immune responses. Furthermore, the induction of ICD induction varies among different approaches, and the distribution of the therapeutic agent within the body influences the level of ICD and the occurrence of toxic side effects. To address these challenges and further boost tumor immunity, researchers have explored nanosystems as inducers of ICD in combination with tumor immunotherapy. This review examines the mechanisms of ICD and different induction methods, with a specific focus on the relationship between ICD and tumor immunity. The aim is to explore the research advancements utilizing various nanomaterials to enhance the body's anti-tumor effects by inducing ICD. This paper aims to contribute to the development and clinical application of nanomaterial-based ICD inducers in the field of cancer immunotherapy by providing important theoretical guidance and practical references. Keywords: tumor immunotherapy, immunogenicity, ICD, DAMPs, nanosystems The advent of malignant tumors poses a considerable threat to human society. Traditional treatments including surgery, radiotherapy and chemotherapy, often exhibit limitations in achieving complete tumor eradication or yield unfavorable prognoses due to tumor cell tolerance and recurrence. Immunotherapy, an emerging field in antineoplastic medicine, has revolutionised cancer treatment. It utilises various approaches, including immune checkpoint inhibitors (ICIs), lymphocyte activating factors, chimeric antigen receptor (CAR)-T cells, other cells, cancer vaccines, lysosomal viruses, and bispecific antibodies. Cancer immunotherapy is a significant milestone in cancer treatment. 1,2 In 2011, the antibody ipilimumab, targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), was approved. Additionally, in 2014, pembrolizumab and nivolumab, both antibodies blocking programmed cell death protein 1 (anti-PD-1) and its ligand 1 (anti-PD-L1), were also approved. 3 However, the low response rate seen in most patients on treatment results in the emergence of immune-related adverse side effects such as cytokine storm, myocarditis and neurotoxicity, which can be fatal due to off-target distribution of ICIs. 4 Hyporesponsiveness to ICIs can be attributed to the "cold tumour" of most tumour patients, including inadequate antigen presentation and an immunosuppressive microenvironment. Therefore, activation to enhance tumour immunogenicity has become a key focus of tumour immunotherapy in this field. 5 Substantial evidence has demonstrated that various tumor immunotherapies, encompassing chemotherapy, radiation therapy, phototherapy, sonic therapy, chemodynamic therapy, ablation treatment, high hydrostatic pressure (HHP), or oncolytic virus (OVs), can elicit Immunogenic cell death (ICD) under specific conditions. This process leads to the release of tumor-associated antigens (TAA) and tumor-specific antigens (TSA), along with the exposure of damage-associated molecular patterns (DAMPs) (Figure 1). Upon release, TAA are typically phagocytosed by antigen-presenting cells (APCs), particularly dendritic cells (DCs), and subsequently presented to T cells. 6 Concurrently, DAMPs facilitate DC maturation, activate cytotoxic T lymphocytes (CTLs), and stimulate the secretion of various pro-inflammatory cytokines associated with innate and adaptive immunity, such as IFN-γ, TNF-α, IL-6, and IL-1β. This orchestrated cascade of events ultimately induces a robust immune response. The activation of anti-tumor T cells and the release of cytok -Abstract Truncated-

Targeting immunogenic cell stress and death for cancer therapy

Consensus guidelines for the detection of immunogenic cell death.

Targeting immunogenic cell death in cancer

Detection of immunogenic cell death and its relevance for cancer therapy

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions

Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy

Immunogenic Cell Death in Cancer Therapy: Present and Emerging Inducers

Immunogenic cell death inducers for enhanced cancer immunotherapy

Mechanisms of immunogenic cell death and immune checkpoint blockade therapy

Immunogenic Cell Death in Cancer Therapy

Immunogenic cell death and its emerging inducers:the next generation immunotherapy

Trial watch: chemotherapy-induced immunogenic cell death in oncology

Natural compound inducers of immunogenic cell death

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

Chapter Seven - Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy

Nanomaterials: leading immunogenic cell death-based cancer therapies

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation

Sensitize Tumor Immunotherapy: Immunogenic Cell Death Inducing Nanosystems

Immunogenic cell death in colorectal cancer: a review of mechanisms and clinical utility

Engineering Immunogenic Cell Death with Nanosized Drug Delivery Systems Improving Cancer Immunotherapy.